Supplemental material
Human Vaccines & Immunotherapeutics
Volume 15, 2019 - Issue 12
Short Report
Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials
Lidia Oostvogelsa GSK, Wavre, Belgium
https://orcid.org/0000-0003-1298-0360View further author information
https://orcid.org/0000-0003-1298-0360View further author information, Thomas C. Heinemanb GSK, King of Prussia, PA, USAhttps://orcid.org/0000-0003-4500-5676View further author information
https://orcid.org/0000-0003-4500-5676View further author information, Robert W. Johnsonc Faculty of Health Sciences, University of Bristol, Bristol, UKhttps://orcid.org/0000-0002-8376-7412View further author information
https://orcid.org/0000-0002-8376-7412View further author information, Myron J. Levind Departments of Pediatrics and Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, USAhttps://orcid.org/0000-0002-7468-106XView further author information
https://orcid.org/0000-0002-7468-106XView further author information, Janet E. McElhaneye Health Sciences North Research Institute, Sudbury, Ontario, Canadahttps://orcid.org/0000-0002-0690-1446View further author information
https://orcid.org/0000-0002-0690-1446View further author information, Peter Van den Steena GSK, Wavre, BelgiumCorrespondence[email protected]
https://orcid.org/0000-0001-7931-1781View further author information
https://orcid.org/0000-0001-7931-1781View further author information, Toufik Zahafa GSK, Wavre, Belgiumhttps://orcid.org/0000-0002-2049-5210View further author information
https://orcid.org/0000-0002-2049-5210View further author information, Alemnew F. Dagnewf GSK, Rockville, MD, USAhttps://orcid.org/0000-0003-4181-058XView further author information
https://orcid.org/0000-0003-4181-058XView further author information, Roman Chlibekg Faculty of Military Health Sciences, University of Defense, Hradec Kralove, Czech Republichttps://orcid.org/0000-0002-7387-3844View further author information
https://orcid.org/0000-0002-7387-3844View further author information, Javier Diez-Domingoh Fundación para el Fomento de la Investigación Sanitaria y Biomédica, Valencia, Spainhttps://orcid.org/0000-0003-1008-3922View further author information
https://orcid.org/0000-0003-1008-3922View further author information, Iris S. Gorfinkeli PrimeHealth Clinical Research, Toronto, Ontario, Canadahttps://orcid.org/0000-0002-8812-941XView further author information
https://orcid.org/0000-0002-8812-941XView further author information, Caroline Hervéa GSK, Wavre, Belgiumhttps://orcid.org/0000-0002-0794-8748View further author information
https://orcid.org/0000-0002-0794-8748View further author information, Shinn-Jang Hwangj Department of Family Medicine, Taipei Veterans General Hospital and National Yang Ming University School of Medicine, Taipei, Taiwanhttps://orcid.org/0000-0003-3217-6193View further author information
https://orcid.org/0000-0003-3217-6193View further author information, Hideyuki Ikematsuk Japan Physicians Association, Tokyo, Japanhttps://orcid.org/0000-0002-3548-4231View further author information
https://orcid.org/0000-0002-3548-4231View further author information, George Kalemal Keyrus Biopharma, Waterloo, Belgium, on behalf of GSKhttps://orcid.org/0000-0002-0535-5930View further author information
https://orcid.org/0000-0002-0535-5930View further author information, Himal Lalb GSK, King of Prussia, PA, USAhttps://orcid.org/0000-0001-7174-1314View further author information
https://orcid.org/0000-0001-7174-1314View further author information, Shelly A. McNeilm Canadian Center for Vaccinology, IWK Health Center and Nova Scotia Health Authority, Dalhousie, University, Halifax, Canadahttps://orcid.org/0000-0001-5444-4166View further author information
https://orcid.org/0000-0001-5444-4166View further author information, , Karlis Pauksensn Department of Infectious Diseases, Uppsala University Hospital, Uppsala, Swedenhttps://orcid.org/0000-0003-2626-7574View further author information
https://orcid.org/0000-0003-2626-7574View further author information, Jan Smetanag Faculty of Military Health Sciences, University of Defense, Hradec Kralove, Czech Republichttps://orcid.org/0000-0002-3770-1754View further author information
https://orcid.org/0000-0002-3770-1754View further author information, Daisuke Watanabeo Department of Dermatology, Aichi Medical University, Nagakute, Japanhttps://orcid.org/0000-0001-6817-3993View further author information
https://orcid.org/0000-0001-6817-3993View further author information, Lily Yin Weckxp Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazilhttps://orcid.org/0000-0003-4949-3582View further author information
https://orcid.org/0000-0003-4949-3582View further author information & Anthony L. Cunninghamq The Westmead Institute for Medical Research, Westmead, University of Sydney, Sydney, NSW, Australiahttps://orcid.org/0000-0002-6744-5667View further author information
https://orcid.org/0000-0002-6744-5667View further author information show allRelated Research Data
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Source:
MASSACHUSETTS MEDICAL SOC
Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
Source:
Taylor & Francis
The global epidemiology of herpes zoster
Source:
Ovid Technologies (Wolters Kluwer Health)
Risk Factors for Herpes Zoster: a Systematic Review and Meta-Analysis
Source:
Oxford University Press (OUP)
Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study
Source:
Springer Science and Business Media LLC
149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial
Source:
Oxford University Press (OUP)
Accumulation of deficits as a proxy measure of aging.
Source:
Hindawi Limited
Linking provided by
